Does Rallies show 13F holders for BEAM?

Yes. Rallies tracks hedge fund and 13F ownership data for BEAM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BEAM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BEAM. It does not provide personalized investment advice.

BEAM (Beam Therapeutics Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Beam Therapeutics Inc. Common Stock (BEAM) is a publicly traded Healthcare sector company. As of May 20, 2026, BEAM trades at $27.21 with a market cap of $2.76B and a P/E ratio of -53.82. BEAM moved +3.06% today. Year to date, BEAM is +1.01%; over the trailing twelve months it is +52.73%. Its 52-week range spans $13.53 to $36.44. Analyst consensus is strong buy with an average price target of $49.91. Rallies surfaces BEAM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BEAM stock?

Hedge funds tracked by Rallies that own BEAM include Farallon Capital, Temasek Holdings, Redmile Group, Eisler Capital, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Beam Therapeutics Inc. Common Stock.

BEAM Key Metrics

Key financial metrics for BEAM
Metric	Value
Price	$27.21
Market Cap	$2.76B
P/E Ratio	-53.82
EPS	$-0.50
Dividend Yield	0.23%
52-Week High	$36.44
52-Week Low	$13.53
Volume	1.79M
Avg Volume	0
Revenue (TTM)	$164.01M
Net Income	$-65.04M
Gross Margin	0.00%

Top Hedge Funds Holding BEAM

Farallon Capital holds 10.13M shares of BEAM, changed +0.71% as of Mar 31, 2026.
Temasek Holdings holds 1.81M shares of BEAM, changed +0.00% as of Mar 31, 2025.
Redmile Group holds 1.24M shares of BEAM, changed -3.75% as of Mar 31, 2026.
Eisler Capital holds 34.38K shares of BEAM, changed +0.00% as of Jun 30, 2024.
Polen Capital holds 9.13K shares of BEAM, changed +0.00% as of Sep 30, 2025.

Latest BEAM News

Beam Therapeutics Reports Durable Phase 1/2 Safety and Efficacy in 29 Patients — May 18, 2026
Beam Therapeutics Backs AlphaDetect with Inaugural Sponsorship to Scale Alpha-1 Testing — May 13, 2026
Beam Therapeutics’ $1.2B Cash Runway Fuels 2026 BLA for Sickle Cell Drug — May 13, 2026
Beam Therapeutics Raises Price Target to $26 and Eyes BLA Submission — Feb 28, 2026
Beam Therapeutics Q4 Loss Shrinks to $0.10, Revenue Soars 9x to $114M — Feb 24, 2026

Recent BEAM Insider Trades

Evans John M. sold 30.08K (~$739.32K) on Apr 1, 2026.
Simon Amy sold 6.70K (~$164.69K) on Apr 1, 2026.
Cavanagh Bethany J sold 3.24K (~$79.69K) on Apr 1, 2026.

BEAM Analyst Consensus

12 analysts cover BEAM: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $49.91.

Common questions about BEAM

Who owns BEAM stock?: Hedge funds tracked by Rallies that own BEAM include Farallon Capital, Temasek Holdings, Redmile Group, Eisler Capital, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Beam Therapeutics Inc. Common Stock.
Does Rallies show 13F holders for BEAM?: Yes. Rallies tracks hedge fund and 13F ownership data for BEAM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BEAM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BEAM. It does not provide personalized investment advice.